Trial Profile
Role of ARNi in Ventricular Remodeling in Hypertensive LVH
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Essential hypertension; Heart failure
- Focus Pharmacodynamics
- Acronyms REVERSE-LVH
- 10 May 2023 Planned number of patients changed from 100 to 80.
- 09 Dec 2020 Planned number of patients changed from 200 to 100.
- 09 Dec 2020 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.